更新的免疫参考页：TTS、G6PD 和 COVID-19 疫苗和过敏
我们最近更新了一些免疫参考页面，以包含有关 COVID-19 疫苗的最新信息和建议。要查看这些页面，请点击以下链接：
微血管内皮细胞： 血栓形成伴血小板减少综合征 (TTS)
微血管内皮细胞： G6PD 缺乏症和疫苗
微血管内皮细胞： COVID-19 疫苗和过敏
新的免疫参考页面：COVID-19 疫苗接种：劳动力培训和应用流程
由于推出 COVID-19 疫苗需要进行大量免疫接种，因此需要扩大当前的免疫接种队伍。需要专门的培训和教育，以确保免疫接种人员得到适当的培训，以便安全有效地接种每种疫苗。
我们的新参考页面“COVID-19 疫苗接种：劳动力培训和申请流程”详细介绍了有关维多利亚州 COVID-19 免疫接种劳动力每位成员培训要求的常见问题。
要了解更多信息，请点击以下链接：
Raising Children Network - new COVID-19 vaccination: pregnancy and breastfeeding resource
MVEC 与 育儿网 to develop a new resource focused on providing COVID-19 vaccine recommendations for women who are pregnant, breastfeeding or planning pregnancy.
To view this article follow the link below:
COVID-19 vaccination: pregnancy and breastfeeding
Further information on vaccines for pregnant and breastfeeding women can be found via our immunisation reference pages below:
New immunisation reference page: COVID-19 vaccination in children
COVID-19 infections have generally produced more severe disease outcomes in adults and the older population, with children generally experiencing milder symptoms. For this reason, initial COVID-19 vaccine clinical trials and vaccine rollouts focused on the adult population. However, it is recognised that in order to achieve herd immunity within the community, the vaccination of children needs to be considered.
Our new reference page outlines the importance of conducting paediatric focused COVID-19 vaccine clinical trials and summarises the trials that are currently underway.
要阅读更多信息，请点击以下链接：
MVEC: COVID-19 vaccination in children
Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments
Anaphylaxis following immunisation is extremely rare but can be life-threatening if not managed effectively. There are many conditions with similar presentations to anaphylaxis without being true anaphylaxis (eg. vasovagal, anxiety, vocal cord dysfunction) which can make the diagnosis difficult.
The Department of Health and the VicSIS网络 have put together Guidance for differentiating anaphylaxis from acute stress response for vaccine providers and Emergency Departments. This helpful resource provides a comparison of signs and symproms, as well as highlights the importance of measuring tryptase levels in patients with suspected anaphylaxis.
This guidance can be found in the resources section of the below reference page:
New immunisation reference page: COVID-19 vaccines in people with immunocompromise
Despite vaccination being recommended, there is currently minimal data on the safety and efficacy of COVID-19 vaccines in the immunocompromised population. In principle, there are no theoretical safety risks and no vaccine safety signals have been identified for vaccinated people with immunocompromise 到 date. Similar to responses following the administration of other inactivated vaccines in immunocompromised people, a reduced efficacy may occur following vaccination against COVID-19.
Our new reference page collates the various recommendations and guidance available for a broad group of immunocompromising conditions and therapies, as well as providing specific recommendations and/or links where available.
要了解更多信息，请点击以下链接：
MVEC: COVID-19 vaccines in people with immunocompromise
New immunisation reference page: Adverse events following COVID-19 immunisation
All immunisations are medications and all medications do have side effects. For each vaccine there is a known list of common or expected adverse events following immunisation (AEFI) and then a smaller list of serious side effects. Reporting significant adverse events is important to allow for signal detection and investigation as part of post-licensure vaccine safety monitoring.
Our new reference page explores what sort of reactions are common and expected following COVID-19 immunisation, and what sort of reactions warrant reporting.
For more information please refer to the following:
MVEC: COVID-19 vaccine adverse events
美国广播公司新闻：ATAGI 已告诉首相停止对 50 岁以下人群使用阿斯利康疫苗并使用辉瑞，但他们是谁？
The Australian Government’s recent decision to amend Australia’s vaccine program was based on the recommendation provided by ATAGI, following international evidence linking a rare blood-clotting condition to the AstraZeneca vaccine in younger people.
ATAGI is the Australian Technical Advisory Group on Immunisation. They provide recommendations to the Minister for Health regarding the National Immunisation Program (NIP) and other immunisation issues including immunisation research and immunisation policies, procedures and vaccine safety. Comprising of 14 medical experts, the group is co-chaired by Associate Professor Christopher Blyth, a specialist in paediatric infectious diseases, and Professor Allen Cheng, who specialises in epidemiology and public health.
This article summarises the role of ATAGI, including their recent recommendations to the Government regarding the AstraZeneca vaccine.
要阅读更多信息，请点击以下链接：
美国广播公司新闻：ATAGI 已告诉首相停止对 50 岁以下人群使用阿斯利康疫苗并使用辉瑞，但他们是谁？
For more information on ATAGI, please refer to our MVEC reference page:
New immunisation reference page: Thrombosis with thrombocytopenia syndrome
Thrombosis with thrombocytopenia syndrome (TTS) is a newly described serious condition which has been reported in people following receipt of dose 1 of COVID-19 AstraZeneca.
Our new reference page explores what is known about the syndrome including symptoms, rates of occurrence globally, risk factors and the types of investigations that should be performed in patients where TTS is suspected.
To read more please refer to the below link:
MVEC: Thrombosis with thrombocytopenia syndrome
有关原住民和托雷斯海峡岛民的 COVID-19 疫苗信息
这 National Aboriginal Community Controlled Health Organisation (NACCHO) 和 NCIRS have joined together to develop new resources on COVID-19 vaccines for Aboriginal and Torres Strait Islander people. This information includes frequently asked questions surrounding the safety and effectiveness of available vaccines, as well as the immunisation recommendations for special risk groups.
To access these resources please follow the link below:
NACCHO: COVID-19 Vaccine Updates and Information
Further information on the immunisation recommendations for Aboriginal and Torres Strait Islander people can be found on our reference page: